TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
ImmunoIVD AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
37,844
|
33,069
|
28,314 |
| Financial expenses |
986
|
1,134
|
1,056 |
| Earnings before taxes |
8,704
|
2,959
|
3,715 |
| EBITDA |
10,813
|
5,390
|
6,399 |
| Total assets |
27,627
|
22,093
|
20,876 |
| Current assets |
23,726
|
17,910
|
16,757 |
| Current liabilities |
15,940
|
16,674
|
16,124 |
| Equity capital |
11,688
|
5,420
|
4,752 |
| - share capital |
65
|
67
|
67 |
| Employees (average) |
27
|
25
|
23 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
42.3%
|
24.5%
|
22.8% |
| Turnover per employee |
1,402
|
1,323
|
1,231 |
| Profit as a percentage of turnover |
23.0%
|
8.9%
|
13.1% |
| Return on assets (ROA) |
35.1%
|
18.5%
|
22.9% |
| Current ratio |
148.8%
|
107.4%
|
103.9% |
| Return on equity (ROE) |
74.5%
|
54.6%
|
78.2% |
| Change turnover |
5,869
|
4,610
|
4,720 |
| Change turnover % |
18%
|
16%
|
20% |
| Chg. No. of employees |
2
|
2
|
-3 |
| Chg. No. of employees % |
8%
|
9%
|
-12% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.